Exploration of Macrophage-Targeted Gene Therapy in Radiation-Induced Cardiac Injury

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400092357

Enrollment

Unknown

Registered

2024-11-14

Start date

2025-01-01

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiation-Induced Cardiac Injury

Interventions

radiation-induced cardiac injury group:No

Health group:No

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients definitively diagnosed with RIHI exhibit the following: 1. Clinical Symptoms: Patients may experience chest pain, angina, or heart failure. 2. Imaging Studies: Cardiac ultrasound, MRI, or CT can reveal structural and functional changes in the heart. 3. Biomarkers: Elevated levels of BNP above 100 pg/mL or NT-proBNP above 300 pg/mL. 4. Treatment History: The patient has a clear history of thoracic radiation therapy. 2.Age 18-75 years old; 3.No experimental cardiac treatments received in the past 6 months. 4.Can provide written informed consent. 5.Healthy individual.

Exclusion criteria

Exclusion criteria: 1.Patients with severe heart failure, renal failure, or liver failure. 2.Patients with a life expectancy of less than six months. 3.Patients with pacemakers or other implantable cardiac devices. Patients who are participating in other clinical trials. 4.Researchers consider the disease unsuitable for participation in this clinical study.

Design outcomes

Primary

Measure	Time frame
Heart injury marker;	—

Secondary

Measure	Time frame
Whole transcriptome, Metabolome, Proteome;	—

Countries

China

Contacts

Public ContactHe Jinchen

China National Nuclear Corporation 416 Hospital

325223890@qq.com+86 18108516029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026